Skip to main content

Paying for Cures: The Ethics and Economics of Gene Therapies for Rare Diseases

Publication Date:
Updated:

Collection Editor(s):

Collection Editor(s)
Name & Degree
Meghan Halley, PhD, MPH
Work Title/Institution
Senior Research Scholar, Center for Biomedical Ethics, Stanford University School of Medicine
  • Introduction

    Rare diseases, most of which have a genetic basis, collectively affect an estimated 300 million individuals worldwide and are associated with significant morbidity and mortality. Although less than 10% of rare diseases currently have an approved therapy, advances in gene and gene-targeted therapies have brought hope of effective—or even curative—treatment. While the potential for cure has prompted justifiable excitement, the high upfront cost of many of these therapies also raises complex ethical and policy issues.

    In response to these challenges, health economists have proposed a range of revisions to traditional value assessment frameworks to include elements relevant to gene therapy, such as “scientific spillover” and “value of hope,” in addition to “health outcomes and costs.” These efforts are focused on systematically assessing the benefits and costs of these therapies to provide evidence of their value and, by extension, their price. However, a lack of real-world data on the long-term effectiveness of these therapies necessitates that these assessments are inherently based on unconfirmed assumptions. In response, policymakers and payers are increasingly…

    Rare diseases, most of which have a genetic basis, collectively affect an estimated 300 million individuals worldwide and are associated with significant morbidity and mortality. Although less than 10% of rare diseases currently have an approved therapy, advances in gene and gene-targeted therapies have brought hope of effective—or even curative—treatment. While the potential for cure has prompted justifiable excitement, the high upfront cost of many of these therapies also raises complex ethical and policy issues.

    In response to these challenges, health economists have proposed a range of revisions to traditional value assessment frameworks to include elements relevant to gene therapy, such as “scientific spillover” and “value of hope,” in addition to “health outcomes and costs.” These efforts are focused on systematically assessing the benefits and costs of these therapies to provide evidence of their value and, by extension, their price. However, a lack of real-world data on the long-term effectiveness of these therapies necessitates that these assessments are inherently based on unconfirmed assumptions. In response, policymakers and payers are increasingly considering innovative, value-based payment schemes to tie payment for these therapies to patient outcomes over time. 

    Increasing evidence points to inequities in access both within the U.S. and internationally. The tenor of conversations about inequity are likely to increase given the anticipated approval of the first gene therapy for sickle cell disease. The introduction of these therapies also has revealed fault lines within patient communities, with some patients arguing that the emphasis on therapies implicitly devalues their personhood and turns attention away from improving resources to support quality of life for people with disabilities. Addressing the many ethical and economic challenges posed by gene therapies will therefore require engagement with a broad range of stakeholders, a clearer understanding of the goals and values of diverse patient communities, and the development of new methods for measuring and assessing value.
     

Collection Header
Ethical and Policy Issues
Body
Collection Header
Approaches to Value Assessment for Gene Therapies
Body
Collection Header
Coverage, Access and Reimbursement for Gene Therapies
Body
Collection Header
Patient and Family Perspectives on Value
Body
Tags
gene therapy
sickle cell disease
health economics
nusinersen

Share

About ELSIhub Collections

  • ELSIhub Collections are essential reading lists on fundamental or emerging topics in ELSI, curated and explained by expert Collection Editors, often paired with ELSI trainees. This series assembles materials from cross-disciplinary literatures to enable quick access to key information.

ELSIhub Collections